Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies

Mucosal Immunology

Volumn 9, Issue 6, 2016, Pages 1584-1595

  Sips, M ^a,b   Krykbaeva, M ^a   Diefenbach, T J ^a   Ghebremichael, M ^a   Bowman, B A ^a   Dugast, A S ^a   Boesch, A W ^c   Streeck, H ^d   Kwon, D S ^a   Ackerman, M E ^a   Suscovich, T J ^a   Brouckaert, P ^b   Schacker, T W ^e   Alter, G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b GHENT UNIVERSITY   (Belgium)

^c DARTMOUTH COLLEGE   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; AUTACOID; BIOLOGICAL MARKER; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; VRC01 MONOCLONAL ANTIBODY;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ACTIVATION; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RISK; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ADULT; FEMALE; GENE EXPRESSION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MIDDLE AGED; MUCOSA; VIROLOGY; YOUNG ADULT;

ADULT; AIDS VACCINES; ANTIBODIES, MONOCLONAL; BIOMARKERS; CYTOKINES; FEMALE; GENE EXPRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; MACROPHAGES; MIDDLE AGED; MUCOUS MEMBRANE; NEUTROPHILS; PHAGOCYTOSIS; RECEPTORS, FC; YOUNG ADULT;

EID: 84991709184     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.12     Document Type: Article

References (58)

1. Haynes, B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012
2. Moog, C., et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 7, 46-56 (2014
3. Barouch, D.H., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013
4. Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101-104 (2007
5. Zeitlin, L., et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA 108, 20690-20694 (2011
6. DiLillo, D.J., Tan, G.S., Palese, P., & Ravetch, J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014
7. Forthal, D.N., et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180, 1338-1341 (1999
8. Sawyer, L.A., et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6, 341-356 (1990
9. Halper-Stromberg, A., et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989-999 (2014
10. Barouch, D.H., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228 (2013
11. Caskey, M., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487-491 (2015
12. Fridman,W.H. Fc receptors and immunoglobulin binding factors. FASEB J. 5, 2684-2690 (1991
13. Burton, D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706-713 (2002
14. Carrega, P., & Ferlazzo, G. Natural killer cell distribution and trafficking in human tissues. Front. Immunol. 3, 347 (2012
15. Tuijnman,W.B., VanWichen, D.F., & Schuurman, H.J. Tissue distribution of human IgG Fc receptors CD16, CD32 and CD64: an immunohistochemical study. APMIS 101, 319-329 (1993
16. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 U.S. dependent areas 2012. HIV Surveillance Supplemental Report 2014 19 ((No. 3)2014
17. Fukazawa, Y., et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132-139 (2015
18. Chun, T.W., et al. Persistence of HIV in gut-Associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197, 714-720 (2008
19. Masson, L., et al. Genital inflammation and the risk of HIV acquisition in women. Clin. Infect. Dis. 61, 260-269 (2015
20. Summers, C., et al. Neutrophil kinetics in health and disease. Trends Immunol. 31, 318-324 (2010
21. Leno-Duran, E., Munoz-Fernandez, R., Olivares, E.G., & Tirado-Gonzalez, I. Liaison between natural killer cells and dendritic cells in human gestation. Cell. Mol. Immunol. 11, 449-455 (2014
22. Metes, D., et al. Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene. Blood 91, 2369-2380 (1998
23. Selvaraj, P., Rosse,W.F., Silber, R., & Springer, T.A. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 333, 565-567 (1988
24. Masson, L., et al. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex. Transm. Infect. 90, 580-587 (2014
25. Li, Q., et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038 (2009
26. Sips,M., et al. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol. 5, 30-40 (2012
27. Euler, Z., & Alter, G. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res. Hum. Retroviruses 31, 13-24 (2015
28. Jefferis, R., Lund, J., & Pound, J.D. IgG-Fc-mediated effector functions:molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol. Rev. 163, 59-76 (1998
29. Lazar, G.A., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103, 4005-4010 (2006
30. Li, Y., et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85, 8954-8967 (2011
31. Richards, J.O., et al. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7, 2517-2527 (2008
32. Moore, G.L., Chen, H., Karki, S., & Lazar, G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2, 181-189 (2010
33. Kaul, M., & Loos, M. Expression of membrane C1q in human monocytederived macrophages is developmentally regulated and enhanced by interferon-gamma. FEBS Lett. 500, 91-98 (2001
34. Smith, P., DiLillo, D.J., Bournazos, S., Li, F., & Ravetch, J.V. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109, 6181-6186 (2012
35. Chung, A.W., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6, 228ra38 (2014
36. Lewis, G.K. Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142, 46-57 (2014
37. Ferrantelli, F., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 17, 301-309 (2003
38. Banks, N.D., Kinsey, N., Clements, J., & Hildreth, J.E. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18, 1197-1205 (2002
39. Moldt, B., et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189-6196 (2012
40. Bournazos, S., et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243-1253 (2014
41. Hessell, A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951-954 (2009
42. Holl, V., et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173, 6274-6283 (2004
43. Ortiz, A.M., DiNapoli, S.R., & Brenchley, J.M. Macrophages are phenotypically and functionally diverse across tissues in simian immunodeficiency virus-infected and uninfected Asian macaques. J. Virol. 89, 5883-5894 (2015
44. Zigmond, E., & Jung, S. Intestinal macrophages: well educated exceptions from the rule. Trends Immunol. 34, 162-168 (2013
45. Smythies, L.E., et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75 (2005
46. Chenine, A.L., et al. Relative transmissibility of an R5 clade Csimian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J. Infect. Dis. 201, 1155-1163 (2010
47. Nagarajan, S., et al. Ligand binding and phagocytosis by CD16 (Fc gamma receptor III) isoforms. Phagocytic signaling by associated zeta and gamma subunits in Chinese hamster ovary cells. J. Biol. Chem. 270, 25762-25770 (1995
48. Rivas-Fuentes, S., Garcia-Garcia, E., Nieto-Castaneda, G., & Rosales, C. Fcgamma receptors exhibit different phagocytosis potential in human neutrophils. Cell. Immunol. 263, 114-121 (2010
49. Chen, K., et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood 120, 4421-4431 (2012
50. Day, P.M., et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8, 260-270 (2010
51. Deeks, S.G., et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614 (2012
52. Trkola, A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622 (2005
53. Shingai,M.et al. Antibody-mediatedimmunotherapy ofmacaques chronically infected with SHIV suppresses viraemia. Nature 503, 277-280 (2013
54. Klein, F., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118-122 (2012
55. Calantone, N., et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity 41, 493-502 (2014
56. Puga, I., et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat. Immunol. 13, 170-180 (2012
57. Boesch, A.W., et al. Highly parallel characterization of IgG Fc binding interactions. MAbs 6, 915-927 (2014
58. Ackerman, M.E., et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8-19 (2011